ABSTRACT
BACKGROUND: Nutritional status in pediatric patients undergoing heart transplantation (HT) is frequently a focus of clinical management and requires high resource utilization. Pre-operative nutrition status has been shown to affect post-operative mortality but no studies have been performed to assess how nutritional status may change and the risk of developing nutritional comorbidities long-term in the post-transplant period. METHODS: A single-center retrospective chart review of patients ≥2 years of age who underwent heart transplantation between 1/1/2005 and 4/30/2020 was performed. Patient data were collected at listing, time of transplant, 1-year, and 3-year follow-up post-transplant. Nutrition status was classified based on body mass index (BMI) percentile in the primary analysis. Alternative nutritional indices, namely the nutrition risk index (NRI), prognostic nutrition index (PNI), and BMI z-score, were utilized in secondary analyses. RESULTS: Of the 63 patients included, the proportion of patients with overweight/obese status increased from 21% at listing to 41% at 3-year follow-up. No underweight patients at listing became overweight/obese at follow-up. Of patients who were overweight/obese at listing, 88% maintained that status at 3-year follow-up. Overweight/obese status at listing, 1-year, and 3-year post-transplantation were significantly associated with developing metabolic syndrome. In comparison to the alternative nutritional indices, BMI percentile best predicted post-transplant metabolic syndrome. CONCLUSIONS: The results suggest that pediatric patients who undergo heart transplantation are at risk of developing overweight/obesity and related nutritional sequelae (ie, metabolic syndrome). Improved surveillance and interventions targeted toward overweight/obese HT patients should be investigated to reduce the burden of associated comorbidities.
Subject(s)
Heart Transplantation , Metabolic Syndrome , Nutritional Status , Postoperative Complications , Humans , Retrospective Studies , Male , Female , Metabolic Syndrome/etiology , Metabolic Syndrome/epidemiology , Child , Adolescent , Child, Preschool , Postoperative Complications/etiology , Postoperative Complications/epidemiology , Body Mass Index , Pediatric Obesity/complications , Follow-Up Studies , Risk FactorsABSTRACT
BACKGROUND: The size of the Fontan population with end-stage heart failure is growing. In this population, heart transplantation has been the only option. This study sought to investigate the efficacy of ventricular assist device (VAD) support in Fontan patients. METHODS: We conducted a retrospective study of Fontan patients in the Advanced Cardiac Therapies Improving Outcomes Network. We evaluated patient characteristics, and the clinical and physiologic outcomes after VAD implantation. RESULTS: We identified 45 Fontan patients implanted with VAD. The average age of patients was 10 years (interquartile range: 4.5-18) and 30% were female. The majority had a morphologic right ventricle (69%), moderate or greater ventricular dysfunction (83%), and moderate or greater atrioventricular valve regurgitation (65%). The majority of implants were as a bridge to transplantation (76%), and the majority of patients were Interagency Registry for Mechanically Assisted Circulatory Support Profile 2 (56%). The most commonly employed device was the Medtronic HeartWare HVAD (56%). A total of 13 patients were discharged on device support, and 67% of patients experienced adverse events, the most common of which were neurologic (25%). At 1 year after device implantation, the rate of transplantation was 69.5%, 9.2% of patients continued to be VAD supported, and 21.3% of patients had died. Hemodynamically, VAD was effective in decreasing both Fontan and ventricular end-diastolic pressures in some individuals. CONCLUSIONS: VAD is effective in supporting patients with end-stage Fontan failure awaiting heart transplantation. Future research should focus on identifying clinical and physiologic characteristics predictive of a favorable response to VAD support.
Subject(s)
Fontan Procedure , Heart Failure/surgery , Heart-Assist Devices , Registries , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Heart Transplantation , Humans , Male , Retrospective Studies , Treatment OutcomeABSTRACT
In this paper in is reported that nine prescriptions often used in traditional Chinese medicine for the treatment of diseases with fever were tested experimentally for the effect on fever of rats induced by endotoxin. The results are as follows: Da-yuan-decoction, Gan-lu-xiao-du-pill, Lian-pu-decoction, Cai-hao-mixture, Da-huang-huang-lian-jie-du-decoction, Tao-ren-cheng-qi-decorction, Ge-gen-qin-lian-decoction, Yin-qiao-jie-du-decoction etc. can notably reduce fever in rats induced by endotoxin with the exception of Bai-hu-decoction that has no obvious effect on fever-reduction.